权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Translational Laboratory Shared Service

转化实验室共享服务

基本信息

批准号：
9145401
负责人：
Rena Lapidus
金额：
$ 12.55万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9145401
关键词：
Animal Experiments Animals Apoptosis Applications Grants Baltimore Biological Biological Assay Biometry Bone Marrow Cancer Center Cancer Center Support Grant Cell Line Cell Proliferation Cells Cigarette Clinical Clinical Data Clinical Research Clinical Trials Clinical trial protocol document Communication Consultations Correlative Study County Custom DNA Data Doctor of Philosophy Drug Kinetics Evaluation Flow Cytometry Funding Genomics Grant Hematologic Neoplasms Hormone Responsive Human Image In Vitro Institutes Investigational Therapies Journals Laboratories Legal patent Letters Malignant Neoplasms Maryland Medical Medical center Methodology Mission Modeling Molecular Biology Nature Pathology Peer Review Peripheral Blood Mononuclear Cell Pharmacodynamics Pharmacy Schools Phase Physicians Plasma Population Sciences Pre-Clinical Model Protocols documentation Public Health Schools Publications RNA Research Research Personnel Research Support Resources School Dentistry Services Solid Neoplasm Source Specimen Specimen Handling Students System Therapeutic Translating Translational Research Universities abstracting acronyms anticancer research base biobank cancer therapy college cytotoxicity in vitro Assay in vivo medical schools member neoplasm immunotherapy novel novel anticancer drug pre-clinical programs structural biology training opportunity tumor tumor immunology virology

项目摘要

7.0 Abstract: Translational Laboratory Shared Service The Translational Laboratory Shared Service (TLSS) at UMGCC generates preclinical (cell- and animal-based) and clinical data for investigators to support cutting-edge research and provides preliminary data for grant submissions and letters of intent for Phase I/II clinical trials, which is a major thrust of TLSS activity. The TLSS also develops in vitro and in vivo preclinical models for evaluation of novel anticancer agents to translate scientific ideas into therapeutics. The TLSS supports many Phase I/II clinical trials at UMGCC by isolating biological specimens and developing and executing assays for correlative studies to support these trials. The TLSS is unique in that it provides a combination of services and resources usually not offered by any one core, predominantly supporting physicians engaged in clinical and translational research and preclinical investigators, fellows, and students conducting preclinical in vivo studies. The TLSS supports Phase I/II clinical trials, provides access to in vivo tumor models, generates preliminary data for grant applications, supports submission of patent applications, and generates data that provide the basis for new clinical trial protocols. These efforts have resulted in publications that include TLSS staff as coauthors, clearly demonstrating the positive impact the TLSS has on cancer research at UMGCC. Since 2010, the TLSS has provided support for 27 clinical trials, including providing preliminary data for 4 new investigator-initiated trials; carried out over 200 animal experiments through an umbrella animal protocol that streamlines investigators’ access to animal studies; and provided preliminary data to 8 peer-reviewed, funded grant applications. In 2014, the TLSS supported 46 Cancer Center members spanning all 5 research programs (18 percent of all UMGCC members), 63 percent of whom have peer-reviewed funding. The TLSS supports many cancer-related publications annually, many in high-impact journals including Nature Communications and Clinical Cancer Research.

7.0摘要：转化实验室共享服务